Promise Bio
The AI engine Fit Assessment
BetaThe company effectively leverages machine learning for biomarker discovery and therapeutic expansion, demonstrating a strong fit in the healthcare innovation space.
Blurb
Promise Bio utilizes AI to analyze epiproteomics for autoimmune diseases.
HQ Location
Tel Aviv-Yafo (Israel)
Founded
2023
Employees
11 - 50
Total funding raised
$8.30M
Funding Status
Grant, December 16, 2024
Subspaces
- Biomarker Identification
Promise Bio is focused on pioneering precision medicine by utilizing epiproteomic analysis to understand autoimmune diseases. The company employs a cloud-based AI platform to perform comprehensive analyses of standard mass-spectrometry data, revealing insights into protein modifications that affect disease mechanisms.